ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA
August 03, 2021CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the China registrational study CS3010-101 of ... -
FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation
May 05, 2019The Food and Drug Administration (FDA) has approved ivosidenib (TIBSOVO, Agios Pharmaceuticals) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test. -
Agios receives nod for ivosidenib
October 11, 2018Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.
Pharma Sources Insight January 2025
